There has been a paradigm shift in the treatment of rheumatoid arthritis in recent years. Early and aggressive treatment with good control of disease activity has improved the prognosis of the disease, however, there is significant variability in the response of patients to different therapeutic agents. Hence it is essential to find the predictors of response to a drug at baseline so that we can avoid the delay in achieving remission and improve the outcome. Here we review the literature on available predictors for treatment response in general and specifically for methotrexate and biological agents. We also look at specific scores or indices that can help predict the response in individual patients
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA...
Introduction Rheumatoid arthritis (RA) is a chronic, disabling disease that mainly affects the synov...
There has been a paradigm shift in the treatment of rheumatoid arthritis in recent years. Early and ...
Objectives: To identify, by a systematic literature review, predictors of clinical response to metho...
Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate ...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Biological agents represent an important advancement in for the treatment of rheumatoid arthritis (R...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Methotrexate (MTX) is a common first-line treatment for new-onset rheumatoid arthritis (RA). However...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological d...
International audienceThe expanding array of drugs available for treating rheumatoid arthritis is cr...
Abstract Introduction Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis ...
Objective: Methotrexate (MTX) is an important drug for treatment of rheumatoid arthritis; however, t...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA...
Introduction Rheumatoid arthritis (RA) is a chronic, disabling disease that mainly affects the synov...
There has been a paradigm shift in the treatment of rheumatoid arthritis in recent years. Early and ...
Objectives: To identify, by a systematic literature review, predictors of clinical response to metho...
Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate ...
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Biological agents represent an important advancement in for the treatment of rheumatoid arthritis (R...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Methotrexate (MTX) is a common first-line treatment for new-onset rheumatoid arthritis (RA). However...
Objective The objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD...
Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological d...
International audienceThe expanding array of drugs available for treating rheumatoid arthritis is cr...
Abstract Introduction Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis ...
Objective: Methotrexate (MTX) is an important drug for treatment of rheumatoid arthritis; however, t...
ObjectiveThe objective was to predict insufficient response to 3 months methotrexate (MTX) in DMARD ...
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA...
Introduction Rheumatoid arthritis (RA) is a chronic, disabling disease that mainly affects the synov...